As a player in the costly FoB arena with a relatively unknown partner (China’s Livzon Mabpharm—#msg-106600322), EPRS was bound to need more capital fairly soon, but the sharp discount of the offering to the market price is not encouraging.
I commented on another potential hurdle for EPRS in #msg-109502738.
*Assuming exercise of underwriter’s option.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.